Literature DB >> 25697665

Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages.

Christina J van Lier1, Bethany L Tiner1, Sadhana Chauhan1, Vladimir L Motin2, Eric C Fitts1, Matthew B Huante1, Janice J Endsley3, Duraisamy Ponnusamy1, Jian Sha4, Ashok K Chopra5.   

Abstract

We recently characterized the Δlpp Δpla double in-frame deletion mutant of Yersinia pestis CO92 molecularly, biologically, and immunologically. While Braun lipoprotein (Lpp) activates toll-like receptor-2 to initiate an inflammatory cascade, plasminogen activator (Pla) protease facilitates bacterial dissemination in the host. The Δlpp Δpla double mutant was highly attenuated in evoking bubonic and pneumonic plague, was rapidly cleared from mouse organs, and generated humoral and cell-mediated immune responses to provide subsequent protection to mice against a lethal challenge dose of wild-type (WT) CO92. Here, we further characterized the Δlpp Δpla double mutant in two murine macrophage cell lines as well as in primary human monocyte-derived macrophages to gauge its potential as a live-attenuated vaccine candidate. We first demonstrated that the Δpla single and the Δlpp Δpla double mutant were unable to survive efficiently in murine and human macrophages, unlike WT CO92. We observed that the levels of Pla and its associated protease activity were not affected in the Δlpp single mutant, and, likewise, deletion of the pla gene from WT CO92 did not alter Lpp levels. Further, our study revealed that both Lpp and Pla contributed to the intracellular survival of WT CO92 via different mechanisms. Importantly, the ability of the Δlpp Δpla double mutant to be phagocytized by macrophages, to stimulate production of tumor necrosis factor-α and interleukin-6, and to activate the nitric oxide killing pathways of the host cells remained unaltered when compared to the WT CO92-infected macrophages. Finally, macrophages infected with either the WT CO92 or the Δlpp Δpla double mutant were equally efficient in their uptake of zymosan particles as determined by flow cytometric analysis. Overall, our data indicated that although the Δlpp Δpla double mutant of Y. pestis CO92 was highly attenuated, it retained the ability to elicit innate and subsequent acquired immune responses in the host similar to that of WT CO92, which are highly desirable in a live-attenuated vaccine candidate.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alveolar macrophages; Braun lipoprotein; Human monocyte-derived macrophages; Innate immunity; Intracellular survival; Plasminogen activator protease; Yersinia pestis

Mesh:

Substances:

Year:  2015        PMID: 25697665      PMCID: PMC4363157          DOI: 10.1016/j.micpath.2015.02.005

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  60 in total

Review 1.  Resistance of Yersinia pestis to antimicrobial agents.

Authors:  Marc Galimand; Elisabeth Carniel; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

2.  A plasminogen-activating protease specifically controls the development of primary pneumonic plague.

Authors:  Wyndham W Lathem; Paul A Price; Virginia L Miller; William E Goldman
Journal:  Science       Date:  2007-01-26       Impact factor: 47.728

Review 3.  The molecular chaperone concept.

Authors:  R J Ellis
Journal:  Semin Cell Biol       Date:  1990-02

4.  Identification of nitric oxide synthase as a protective locus against tuberculosis.

Authors:  J D MacMicking; R J North; R LaCourse; J S Mudgett; S K Shah; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Characterization of late acyltransferase genes of Yersinia pestis and their role in temperature-dependent lipid A variation.

Authors:  Roberto Rebeil; Robert K Ernst; Clayton O Jarrett; Kristin N Adams; Samuel I Miller; B Joseph Hinnebusch
Journal:  J Bacteriol       Date:  2006-02       Impact factor: 3.490

6.  The groES and groEL heat shock gene products of Escherichia coli are essential for bacterial growth at all temperatures.

Authors:  O Fayet; T Ziegelhoffer; C Georgopoulos
Journal:  J Bacteriol       Date:  1989-03       Impact factor: 3.490

7.  Evaluation of the role of the Yersinia pestis plasminogen activator and other plasmid-encoded factors in temperature-dependent blockage of the flea.

Authors:  B J Hinnebusch; E R Fischer; T G Schwan
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

Review 8.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

9.  Yersinia pestis survival and replication within human neutrophil phagosomes and uptake of infected neutrophils by macrophages.

Authors:  Justin L Spinner; Seth Winfree; Tregei Starr; Jeffrey G Shannon; Vinod Nair; Olivia Steele-Mortimer; B Joseph Hinnebusch
Journal:  J Leukoc Biol       Date:  2013-11-13       Impact factor: 4.962

10.  Early host cell targets of Yersinia pestis during primary pneumonic plague.

Authors:  Roger D Pechous; Vijay Sivaraman; Paul A Price; Nikolas M Stasulli; William E Goldman
Journal:  PLoS Pathog       Date:  2013-10-03       Impact factor: 6.823

View more
  7 in total

1.  A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Authors:  Jian Sha; Michelle L Kirtley; Curtis Klages; Tatiana E Erova; Maxim Telepnev; Duraisamy Ponnusamy; Eric C Fitts; Wallace B Baze; Satheesh K Sivasubramani; William S Lawrence; Igor Patrikeev; Jennifer E Peel; Jourdan A Andersson; Elena V Kozlova; Bethany L Tiner; Johnny W Peterson; David McWilliams; Snehal Patel; Eric Rothe; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

2.  Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.

Authors:  Jourdan A Andersson; Jian Sha; Michelle L Kirtley; Emily Reyes; Eric C Fitts; Sara M Dann; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Two Isoforms of Yersinia pestis Plasminogen Activator Pla: Intraspecies Distribution, Intrinsic Disorder Propensity, and Contribution to Virulence.

Authors:  Svetlana V Dentovskaya; Mikhail E Platonov; Tat'yana E Svetoch; Pavel Kh Kopylov; Tat'yana I Kombarova; Sergey A Ivanov; Rima Z Shaikhutdinova; Lyubov' V Kolombet; Sadhana Chauhan; Vitaly G Ablamunits; Vladimir L Motin; Vladimir N Uversky; Andrey P Anisimov
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

4.  Impact of Gentamicin Concentration and Exposure Time on Intracellular Yersinia pestis.

Authors:  Tiva T VanCleave; Amanda R Pulsifer; Michael G Connor; Jonathan M Warawa; Matthew B Lawrenz
Journal:  Front Cell Infect Microbiol       Date:  2017-12-11       Impact factor: 5.293

Review 5.  Plague vaccines: new developments in an ongoing search.

Authors:  Jason A Rosenzweig; Emily K Hendrix; Ashok K Chopra
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-18       Impact factor: 4.813

6.  Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague.

Authors:  Bethany L Tiner; Jian Sha; Yingzi Cong; Michelle L Kirtley; Jourdan A Andersson; Ashok K Chopra
Journal:  NPJ Vaccines       Date:  2016-10-13       Impact factor: 7.344

Review 7.  Yersinia pestis Plasminogen Activator.

Authors:  Florent Sebbane; Vladimir N Uversky; Andrey P Anisimov
Journal:  Biomolecules       Date:  2020-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.